Betaliq
Tarpon Springs, US · Founded 2018 · Delaware corporation · 3 known investors
Betaliq is a clinical-stage pharmaceutical company developing topical eye-drop therapies for glaucoma using a licensed water-free drug delivery platform (EyeSol). Its lead candidate, BTQ1902, is a timolol suspension in development for elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Also known as Betaliq Inc. · Betaliq, Inc.
Founders & leadership
Board
Investors · 3
Also in the syndicate · 1
Reported raises · per SEC filings
Form D private placements$6.4M disclosed across 2 of 3 rounds · 2019–2025
▶$416.3KraisedJun 2025 · 8 investors · BiotechnologyRule 506(b)
- Oliver SchlueterExecutive Officer, Director
- Christian RoeskyDirector
- Barry ButlerExecutive Officer, Director
- Christopher JonesDirector
- Albert RudickDirector
- Offering amount
- $5M
- Amount sold
- $416.3K
- Sales commissions
- $29.7K
- Placement agents
- Collage Venture Partners, LLC, Arcadia Securities, LLC
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedJul 2019 · 68 investors · BiotechnologyRule 506(b)
- Haley LemonExecutive Officer
- Oliver SchluterExecutive Officer, Director
- Barry ButlerExecutive Officer, Director
- Christian RoeskyDirector
- Offering amount
- $10M
- Amount sold
- $6M
- Sales commissions
- $700K
- Placement agents
- CIM Securities, LLC, Arcadia Securities, LLC
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Betaliq, Inc. is a clinical-stage pharmaceutical company focused on topical ophthalmic therapies for glaucoma. It holds exclusive rights, for glaucoma indications, to Novaliq's EyeSol technology, a water-free drug delivery platform for eye drops. The company positions its programs against limitations of conventional water-based eye drops, including drop volumes of 40-50 microlitres that exceed the eye's capacity, limited spreading due to surface tension and the tear film lipid layer, reflex blinking and tearing, and resulting topical bioavailability reported at 1-10%.
Its lead candidate, BTQ1902, is timolol maleate 0.5% suspended in perfluorohexyloctane (EyeSol), in development for elevated intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. The EyeSol vehicle allows formulation as a non-preserved suspension in a multi-dose bottle without preservatives or phosphates. Betaliq reports positive Phase 2a data for BTQ1902 and is advancing toward a Phase 3 trial. Additional pipeline programs, both with global rights, are BTQ2301 (latanoprost solution in EyeSol) and BTQ2302 (a timolol and latanoprost combination). The company states an intention to build a broader glaucoma portfolio and to expand into other general ophthalmology and specialty eye care indications through partnerships.
Founding story
Betaliq was founded in 2018 through a collaboration between BLP Management Group and Novaliq GmbH. The arrangement gave Betaliq exclusive rights to Novaliq's proprietary EyeSol water-free ophthalmic drug delivery platform for glaucoma therapies.
Business model
Betaliq develops pharmaceutical product candidates in-licensed from a platform technology owner (Novaliq's EyeSol) and operates a virtual management model, which it describes as allowing efficient resource allocation as it approaches clinical milestones. It cites partnerships as the route for expanding beyond glaucoma into other ophthalmic indications.
Traction
BTQ1902 has completed Phase 2, with positive Phase 2a data reported, and the company is advancing toward a single Phase 3 trial. BTQ2301 is listed as in accelerated development; BTQ2302 is an earlier-stage combination program. Global product rights are held for all three programs.
Latest developments
Betaliq states it is advancing BTQ1902 toward a Phase 3 clinical trial following positive Phase 2a results, and lists BTQ2301 (latanoprost in EyeSol) as being in accelerated development.
▸Full profile — market position, technology, go-to-market, history
Market position
The company addresses glaucoma, described as a leading cause of irreversible blindness affecting over 80 million people as of 2020 and projected to exceed 111 million by 2040. It frames existing options - eye drops, laser therapy and surgery - as limited by poor patient adherence, side effects and incomplete intraocular pressure control.
Technology
All Betaliq programs are built on EyeSol, described as the first and only water-free technology for ophthalmic products, licensed from Novaliq. Stated features include extended residence time on the eye (from minutes to hours), higher bioavailability of active ingredients, tolerability and safety, reduced systemic exposure due to small drop size, preservative-free formulation, and ocular surface benefit. The company states EyeSol is physically, chemically and physiologically inert, is not catabolised or metabolised, is biocompatible without bioaccumulation, and has been safety tested in more than 2,500 patients. EyeSol has been used in products with FDA and EMA approvals and CE certification, including MIEBO (perfluorohexyloctane ophthalmic solution), VEVYE (cyclosporine ophthalmic solution 0.1%), VEVIZYE (ciclosporin 0.1% eye drops), and NovaTears/EvoTears and NovaTears/EvoTears +Omega-3.
Go-to-market
Patients with elevated intraocular pressure due to primary open-angle glaucoma or ocular hypertension, treated with topical prescription eye drops.
History
Following its 2018 formation as a collaboration between BLP Management Group and Novaliq GmbH, Betaliq completed an $8 million Series A round in 2019 led by Brookline Capital Markets. It subsequently completed Phase 2 work on lead candidate BTQ1902, reporting positive Phase 2a data, and is preparing a planned Phase 3 trial.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsBetaliq completed an $8 million Series A funding round led by Brookline Capital Markets.
$8M source ↗
Betaliq was founded via a collaboration between BLP Management Group and Novaliq GmbH, under which it holds exclusive rights to Novaliq's EyeSol water-free ophthalmic drug delivery platform for glaucoma therapies.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Betaliqbetaliq.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Betaliq do?
- Clinical-stage pharmaceutical company developing water-free EyeSol-based topical eye drops for glaucoma.
- Who are Betaliq's investors?
- Betaliq's investors include Evolution VC Partners, Green Park & Golf Ventures.
- How much funding has Betaliq raised?
- Betaliq has disclosed $6.4M raised across 2 of its 3 known rounds.
- Where is Betaliq headquartered?
- Betaliq is headquartered in Tarpon Springs, US.